Key clinical point: Women with breast cancer may be receiving treatments that are discordant with guideline recommendations for genetic subtypes of disease.
Major finding: Compared with patients without a BRCA mutation, patients who tested positive for BRCA1/2 were 78% less likely to receive postlumpectomy radiotherapy and 76% more likely to receive chemotherapy for early-stage, hormone-positive disease.
Study details: A retrospective study of 20,568 women with stage 0-III breast cancer.
Disclosures: The study was funded by the National Institutes of Health and the California Department of Public Health. The investigators reported relationships with Myriad Genetics, Genomic Health, Roche, and other companies.
Kurian AW et al. JAMA Oncol. 2020 Feb 6. doi: 10.1001/jamaoncol.2019.6400.